Sinopharm Group Co (SHTDY)
OTHER OTC:SHTDY
Want to see SHTDY full AI Analyst Report?
SHTDY Stock Chart & Stats
$13.13
-$0.11(-0.80%)
At close: 4:00 PM EST
$13.13
-$0.11(-0.80%)
Day’s Range― - ―
52-Week Range$10.79 - $14.04
Previous CloseN/A
Volume2.10K
Average Volume (3M)1.38K
Market Cap
$6.83B
Enterprise Value$92.65B
Total Cash (Recent Filing)$61.60B
Total Debt (Recent Filing)$108.65B
Price to Earnings (P/E)6.5
Beta0.16
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.75%
Share Statistics
EPS (TTM)11.35
Shares Outstanding268,362,150
10 Day Avg. Volume773
30 Day Avg. Volume1,375
Financial Highlights & Ratios
PEG Ratio-4.39
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market Cap13.56
Enterprise Value/Revenue0.16
Enterprise Value/Gross Profit2.23
Enterprise Value/Ebitda4.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extensive Distribution NetworkA nationwide logistics and sales network is a durable competitive asset for a pharmaceuticals distributor. Scale and established hospital/pharmacy relationships support steady order flow, operational efficiencies, and higher switching costs for suppliers, helping sustain core revenue and fulfillment capabilities over time.
Solid Cash GenerationConsistent conversion of earnings into cash provides financial resilience: positive operating and free cash flow support working capital needs, dividend payments and reinvestment even as growth softens. This cash quality cushions the business against cyclical pressures and funds operational priorities.
Diversified Healthcare Revenue MixA mix of wholesale distribution, device/diagnostic sales, and retail reduces concentration risk tied to any single product or tender. This structural diversification allows shifting focus to higher-margin segments and insulates overall sales from isolated pricing or procurement changes in one channel.
Bears Say
Weakening Revenue TrendA multi-year slowdown from earlier stronger growth signals structural headwinds such as tougher tendering dynamics, pricing pressure, or market saturation. Continued revenue contraction reduces scale benefits, complicates margin recovery and limits capacity to invest in growth or network upgrades.
Margin CompressionLow and falling margins sharply constrain the firm's ability to absorb cost inflation or fund strategic initiatives. For a distribution-led model, margin erosion reduces cash buffer, weakens returns on capital and heightens sensitivity to procurement/tender pricing shifts over the medium term.
Rising LeverageA meaningful increase in leverage reduces financial flexibility and raises interest and refinancing risk, especially given thin margins. Higher debt restricts the company's ability to pursue acquisitions, invest in logistics or capex, and elevates vulnerability to cash-flow shocks over the next several quarters.
Sinopharm Group Co News
SHTDY FAQ
What was Sinopharm Group Co’s price range in the past 12 months?
Sinopharm Group Co lowest stock price was $10.79 and its highest was $14.04 in the past 12 months.
What is Sinopharm Group Co’s market cap?
Sinopharm Group Co’s market cap is $6.83B.
When is Sinopharm Group Co’s upcoming earnings report date?
Sinopharm Group Co’s upcoming earnings report date is Aug 31, 2026 which is in 86 days.
How were Sinopharm Group Co’s earnings last quarter?
Currently, no data Available
Is Sinopharm Group Co overvalued?
According to Wall Street analysts Sinopharm Group Co’s price is currently Overvalued.
Does Sinopharm Group Co pay dividends?
Sinopharm Group Co pays a Annually dividend of $0.471 which represents an annual dividend yield of 3.75%. See more information on Sinopharm Group Co dividends here
What is Sinopharm Group Co’s EPS estimate?
Sinopharm Group Co’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Group Co have?
Sinopharm Group Co has 268,362,150 shares outstanding.
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sinopharm Group Co?
Currently, no hedge funds are holding shares in SHTDY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinopharm Group Co Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.49%
12-Months-Change
Fundamentals
Return on Equity
8.62%
Trailing 12-Months
Asset Growth
3.79%
Trailing 12-Months
Company Description
Sinopharm Group Co
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---